Merck & Co., Inc. (NYSE:MRK)
Why are short-sellers avoiding Merck & Co., Inc. (NYSE:MRK)?
Short-sellers’ avoidance of Merck appears to be due to its high dividend yield (3.9%) and its ability, thus far, to navigate the patent cliff with grace. Merck lost its blockbuster asthma drug Singulair to patent expiration last year and this year will lose Temodar and Maxalt, which contributed around $1.5 billion in annual sales. Even so, Merck is still expected to earn about $11 billion in profits this year.
Do investors have a reason to worry?
I’ve been an advocate in favor of Merck in the past, but I’m honestly concerned about the disruptive potential that new SGLT2 inhibitors Invokana by Johnson & Johnson (NYSE:JNJ) and Forxiga by Bristol-Myers Squibb Co. (NYSE:BMY) and AstraZeneca plc (ADR) (NYSE:AZN) could have on the Type 2 diabetes market. Merck’s Januvia — a $4.1 billion drug — was beaten fair and square in a head-to-head trial with Invokana, which the FDA just approved. I’d say Merck shareholders definitely have a few concerns on their plate.
Exxon Mobil Corporation (NYSE:XOM)
Why are short-sellers avoiding Exxon Mobil Corporation (NYSE:XOM)?
As the world’s largest oil company by revenue, ExxonMobil shouldn’t garner too much short interest. Having diversified assets around the world gives ExxonMobil immense pricing power and cash flow that few other integrated oil and gas companies possess. ExxonMobil is also the largest corporate dividend payer, pumping out $10.75 billion in dividends to shareholders annually.
Do investors have a reason to worry?
The two biggest concerns for integrated oil and gas companies of Exxon’s size are political worries and the underlying price of oil. The first worry is but an afterthought for ExxonMobil, which has operations around the globe and is shielded from major production snafus. A big drop in the price of West Texas Intermediate or Brent crude, though, could be a problem. Weakness in the eurozone and a lack of strength in the U.S. economy could trigger some minor worries, as that could ultimately result in lower oil demand from those regions. However, over the long run, investors in ExxonMobil should be sleeping well at night.
The Procter & Gamble Company (NYSE:PG)
Why are short-sellers avoiding The Procter & Gamble Company (NYSE:PG)?
Consumer-products company Procter & Gamble is rarely going to draw the ire of short-sellers because the majority of what it sells is very price-inelastic. In other words, regardless of whether the economy is up or down, P&G is still going to make the sale to the consumer. In its second-quarter results released back in January, P&G delivered 3% organic growth and grew its market share in many domestic segments.
Do investors have a reason to worry?
If we were looking at P&G a year ago, I’d have said there was cause for concern. However, P&G has adjusted its prices and more effectively used its marketing tactics, including social media, to reach out to its consumer base. Organic growth of 3% might be unimpressive, but for a consumer-products company of its size that’s facing slowing spending in the U.S. and Europe, that’s phenomenal. P&G isn’t a company I’d recommend any short-sellers bet against.
Which Dow component would you most like to call your own? Share your thoughts in the comments section below!
The article The Dow’s 5 Most Loved Stocks originally appeared on Fool.com.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool owns shares of General Electric and Johnson & Johnson and recommends Coca-Cola, Johnson & Johnson, and Procter & Gamble.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
